Summary: Biological processes which inight explain the association of pteridine excretion with proliferation are still unknown. Difficulties in the analysis and the determination of naturally occurring pteridines are described. The best quantitative estimations were achieved when measurement of non-reduced forms was attempted. The performance characteristics of such a method for neppterin by high performance liquid chromatography on reversed phase are given. Enhanced proliferation and dedifferentiation in cell cultures and organisms is paralleled by excretion of unconjugated pteridines into the medium or urine. Urinary neopterin in healthy subjects and in patients with benign diseases was only significantly raised in patients with viral diseases. Howevei, an elevation of urmary neopterin occurred in a wide variety of malignant diseases. In haematologic neoplasias correlatipns of neopterin values to clinicäl features, to tumour staging, and to laboratory data were apparent. The clinicäl Utility of neopterin measurement was also demonstrated in patients with gynaecologic tumours, particularly in patients with ovarian carcinoma. In both homogenepus patient groups the neopterin assay may provide an additional aid for prognosis and for monitoring therapy. Comparison of the neopterin assay with already established tumour marker substances at least revealed no inferiority in sensitivity. The present results justify extensive investigations in prder to eväluate further the clinicäl applicäbility of the neopterin assay. 
Introduction
^^ is probably because the pteridines have been inBiological functions of unconjugated pteridines vestigated only recently and only by a few laboratories. In contrast to the field of purines, the biological func-
The reason for this comparatively late research into their tions of most unconjugated pteridines are unknown, biological role lies certainly in analytical difficulties. In despite their common occurrence in various organisms.
some cases the problems of Isolation and characterization are caused by the low concentrations of pteridines in biological samples; they are generally present only in trace amounts (1, 2) . An exception is the relatively high concentrations which are found in the wings ofPteridae butterflies. Other problems result from chemical abnormalities such äs photolability, uncpmmon solubility and lack of melting points.
An excellent review of pteridine chemistry up to 1963 is given by Pfleiderer (2) . Interesting and more recent aspects of analysis were described in the reports of the pteridines symposia held at Konstanz in 1973 (3) and at La Jolla, California, in 1978 (4), (5) (6) (7) (8) (9) (10) (11) (12) .
Pteridines are found äs pigments in the skin and eyes of insects, amphibians and fish. The essential metabolic roles of unconjugated pteridines which were known or had been proposed till 1982 are summarized in a review by Rembold (1) . Today, the best established function is that of 5,6,7,8-tetrahydrobiopterin which serves äs cofactor for a set of enzymes which hydroxylate phenyl· alanine, tyrosine and tryptophan using molecular oxygen (13, 14) . A siniilar enzyme catalyses the conversion of glyceryl ethers to carboxylic acids and glycerol (15). Participation of pteridines in the photosynthetic electron transport of photosynthetic bacteria and chloroplasts of higher plants has been proposed by several authors (16, 17) . The possibility of a regulatory function of pteridines in melatonin biosynthesis (18) and of an interactiori between pteridines and DNA (19) requires more detailed research.
Biosynthesis of the pteridine ring Unconjugated pteridines are synthesized de novo by mammals and by other higher animals äs reported by Kraut et al. (20) and byPabst &Rembold(2l). As shown in figure l, during biosynthesis the pteridine ring arises from the purine ring. GTP (guanosine triphosphate) is converted enzymatically to dihydroneopterin triphosphate. The äbility of guanine compounds to serve äs precursors of pteridines was investigated in larvae ofDrosophila melanögaster by Brenner-Hohach ScLeuthärdt (22) and in butterflyspecies by Weygand et al. (23) and by Watt (24) . Jones & Brown presented direct evidence that dihydro·· neopterin is formed enzymatically mEscherichia coli from GTP (25) . The same synthetic scheme is also established in Comamönassp. (26) , in the büllfrog, Rana catesbeiana (27) , in Drosophila melanögaster (28) , in the Chinese hamster and the Syrian golden hamster (29) .
Biological conversion and degrädation of pteridines
As shown in a reaction scheme by Rembold (30) These are the same reactions that occur in the degradation and thus these pteridines are found äs terminal metabolites in culture media of cells and in urine. The different excretion products depend on the presence or absence of specific enzymes. For example, the occurrence of lumazines requires the presence of a pterin deaminase. For most organisms the pteridines represent true terminal catabolites (1).
Analy tical Methods for Unconjugated Pteridines
The diagnostic significance of tumour markers is strongly influenced by the method available for their measurement. As the pteridines occur in extremely small amounts in biological materials the analytical method has to be sensitive, specific and accuiate. For clinical laboratory use the practicability of the assay has to be taken into consideration.
A sensitive growth assay using the microorganism Crithidia fasciculata has been reported by Guttman (31) . This assay, which is applicable for Zr-biopterin and its reduced forms has been most frequently used, but it is very tedious and time consuming.
In newer methods pteridines are detected by their native fluorescence which generally gives a specific and sensitive determination.
Determination of pteridines by paper chromatography (32) (39) (40) (41) (42) . Although sensitivity and specificity is Increased compared to the methods cited above, the practicability is diminished by a necessary preliminary purification of the biological material. Practicability and accuracy can be optimized to a greät extent by HPLC-anälysis on reversed phäse. Such assays for the estimation of unconjugated pteridiries have been described by several laboratories (42) (43) (44) (45) (46) , För example the HPLC method on reversed phäse was optimized for the urinary neopterin measurement (47) : Rapid Separation of urine constituents was achieved by an isocratic solvent System on a 10 reversed phäse C 18 column following a sample preparation through C 18 cartridges. Subsequent to elution of neopterin a flow and composition gradient was established in Order to accelerate column purification.
Neopterin has been monitored using a spectral fluorescence detector. In order to reduce the effect of physiological variations in urine concentration the neopterin concentration was related to that of creatinine; for this reason it was advantageous that creatinine could be estimated simultaneously with a spectral absorption detector (48) . As shown in table l, this method provides good performance characteristics and is easy to handle. The assay was modified by using a guard column (49) , thus enabling automation for routine clinical laboratory use. A gas chromatography-mass fragmentography method (50) seems particularly suited äs a reference method. As it is difficult to analyse many samples during one day this accurate assay is not useful for routine laboratories. A radioimmunoassay for biopterin (51) represents an attractive alternative if the HPLC equipment is not already at hand. Thus an i-erythro-biopterin specific assay is applicable to body fluids and tissues. Measurement of the total amount of reduced and oxidized pteridines after conversion to the fully oxidized state has also been reported (41, 52) . Since the use of test substances showed a recovery of 80-90%, quantification of reduced forms using this technique does not yet seem possible with the desired precision and accuracy.
The optimized analytical techniques have enabled research into the relationship between pteridines excretion and biological parameters. The present investigations were undertaken to study the behaviour of pteridine excretion in cancer patients.
Excretion of Pteridines from Cells, Plants and Animals
Pteridine excretion äs indicator of cell proliferation Various procaryont and eucaryont organisms excrete pteridines during the growth phase (53.). E. coli secretes monapterin in the logarithmic growth phase. At the switch to the stationary phase the excretion of monapterin experiences a burst, whereas in the stationaiy phase E. coli hardly releases any pteridines. The slime mouldPhysarum polycephalwn excretes isoxanthopterin andAcetabularia mediterranea pterin-6-carboxylic acid into the medium. In the same manner the rapid growth ofCalanchoe tubiflora is paralleled by release of iso·· xanthopterin, and the germination of potatoes (Solanum tuberosum) by excretion of isoxanthopterin and monapterin into the medium.
Pteridine excretion äs indicator of rapid or malignant proliferation Association of pteridines with high metabolic activity in dedifferentiating tissues was indicated by Kokolis & Ziegler (54) and by Kokolis et al. (55) . Elevated concentrations of tetrahydrobiopterin were detected in the skin of Triturus species during larval development and in the regeneration blastema of the adult newt after tau amputation. Interestingly, the growth rate of the regeneration bud was strongly inhibited by injection of isoxanthopterin after amputation. Kokolis et al. (56) compared tetrahydrobiopterin levels in tissues from human squamous cell carcinoma with levels in tissues from rats. In the tumour samples the ratio of tetrahydrobiopterin to riboflavin was much higher than in normal tissue with high metabolic activity. Furthermore, Kokolis & Ziegler (57) reported that tetraĥ ydrobiopterin levels in the blood of tumour-bearing rats (Ascites AH 130 and Guerin T-8 tumours) were raised compared with those in healthy rats. Albrecht and coworkers (58) investigated the biopterin content of several cell lines in human neuroblastoma. They observed markedly higher biopterin levels in adrenergic neuroblastoma, glioblastoma and fibroblastlike cell lines. 6-Hydroxymethyl-pterin was also shown to be excreted into the medium in large amounts by cancer cells (59) . Increased excretion of a fluorescent component was found in the urine of mice beäring .Ehrlich ascites tumour (35) . This metabolite was identified äs 6-hydroxylumazine which originates during analysis from 7,8-dihydro-6-hydroxylumazine (36) . The urinary excretion of this pteridine related to indoxylsutfate (excreted at a constant rate in mice) was determiried äs 0.65 ± 0.21 (mean ± SD) for 110 healthy mice. In contrast, this quotient increased to 2.47 ± 1.09 (mean ± SD) for 120 Ehrlich ascites tumour-bearing mice on the fifth day after tumour transplantation. As shown in figure 2 this quotient üicreases up to the sixth day and then falls; there is a similar increase in the number of tumour cells. In these animals, tumour proliferation is paralleled by the excretion of 7,8-dihydro-6^hydroxylumazme, which thus acts äs an index of tumour growth. neopterin/creatinine ratio and age was demonstrated.
Children have notably higher urinary mean neopterin/ creatinine values (47, 67) . This relationship may result to some extent from the distinct Variation of urinary creatinine levels with sex and age.
Since the most useful application of tumour markers at the present time is the monitoring of treatment, the oscillation of the neopterin excretion over a longer time period is of interest. The urinary neopterin levels were determined daily over a one-month period in 4 normal individuals (47) . The individual v riance coincided with the r nge found to be typical for people of the same sex and age. In order to assess neoplasias the upper normal limits of urinary pteridines must be statedL Rokos and coworkers (45) considered values of neopterin ab ve 447 μπιοΐ/τηοΐ creatinine ΐο be abnormal. H wever, this limit which was based on the estimation of neopterin and biopterin following an oxidation Step prior to analysis by HPLC, did not take into account the sex-and age-dependent variations of urinary neopterin levels (49, 67, 69) . Recommended upper levels of normal excretion, which do take into account the sex-and age-dependence of urinary neopterm have recently been stated (49, 69) , Table 3 shows the mean and median values and the upper confidence limits for eaeh sex and age group. These limits, calculated according toLieberni nn (70) , include with 95% probability 97.5% of healthy subjects, thus enabling the accurate Interpretation of results.
Excretion of Pteridines in Patients with Benign Diseases
Measurement of urinary pteridines is of clinical value in the recognition of variants in phenylketonuria patients (71, 42, 64 deficiency (75, 64) were demonstrated. These data were confirmed by Dhondt and coworkers (67) using age-paired comparisons. Significantly (p < 0.0001) raised neopterin levels occur in patients with viral diseases (43, 66) . Urinary neopterin levels were affected moderately by benign cell renewal (76) . In 5 patients who had undergone surgery (laparotomy) the highest neopterin excretion was observed between the third and the sixth day. On the day of the highest level, the mean neopterin value ± SD in neopterin per mol creatinine was 233 ± 40. In figure 3 a typical change in urinary neopterin levels following laparotomy due to cholelithiasis is depicted. Slightly increased neopterin levels were observed in patients with hyper-regenerative bone marrow (49) . In patients with haemolytic anaemia the mean neopterin value was only a little higher than that of healthy controls. In 5 patients with renal insufficiency coupled with renal anaemia, the mean urinary neopterin level increased nearly to the upper normal limit (45) . In 9 patients with renal insufficiency and in 7 patients with psoriasis, mean values above the normal limit were found (66).
Excretion of Pteridines in Patients with Malignant Diseases
Studies in advanced neoplasias of different sites Early reports on patients with malignancy showed a raised excretion of fluorescent urinary components, which were very probably pteridines (77, 78) . A pterin excreted by patients with cancer and by malignant cells in tissue culture media was originally tentatively identified äs pterin-6-aldehyde (33), but was later identified äs 6-hydroxymethylpterin (59) . A contemporary investigation using the same thin layer Chromatographie assay System for urine samples showed clearly that the mere presence of pterin-6-aldehyde is not diagnostic for cancer (79 high mean values were shown in poorly differentiated chronic lymphoid leukaemia and in non-Hodgkin's lymphoma occurring in both poorly and well-differentir. ated forms.
In patients with chronic lymphocytic leukaemia and with non-ffodgkin's lymphoma the urinary neopterin levels correlated with the stage of disease (76) . The mean neopterin values in stages I and II were significantly raised compared to the control group. The highest mean values were observed in patients with stages III and IV and with large tumour burdens.
In patients with chronic leukaemias the urinary neopterin excretion correlated with occürrence of hepatosplenomegalia and with haematological criterias such äs serum levels of leukocytes, platelets and haemoglobin.
These data suggest that the urinary neopterin assay can advantageously supply clinical and laboratory parameters to assess the extent, progression and outcome in haematological neoplasias. The clinical Utility of the urinary neopterin measurement was improved in patients with gynaecological tumours (69) . There was a significant difference (p < 0.01) between the mean values of 63 untreated tumour patients and 96 healthy women compared in each case to the age-paired group. Table 5 shows the clinical significance of the urinary neopterin estimation.
Of patients examined at the onset of therapy, 41/63 (65%) exhibited neopterin levels above the upper normal limit.
Tab. 4. Urinary neopterin levels ( neopterin per mol creatinine) and frequency of values exceeding the upper limits of normal in patients with haematological neoplasias,*) haemolytic anaemia and benign paraproteinaemia. *) Data from Hausen et al. (49) **) Upper limits tested according to Liebermann (70) containing with 95 % probability 97.5% of healthy subjects. (70) containing with 95% probability 90% of healthy women. It is noticeable that in follow-up treatment in patients with gynaecological malignancies the neopterin assay provides even better results. In 53/72 (74%) patients the clinical and X^ray findings corresponded well with the urinary neopterin levels. Both reports (49, 69) suggest a potential usefulness of the urinary neopterin measurement in the assessment of haematologic neoplasias and of gynaecologic tumours. A clinical applicability of the neopterin assay in these malignancies appears likely.
Diagnosis
Comparison of the urinary neopterin assay with other tumour markers The initial burst of enthusiasm in the field of tumour markers has greatly disappeared during the past several years, and this field has been the subject of considerable questioning (80, 81) . Problems involved in this area may partly be caused by methodic difficulties which lead to inconsistent results. Often somewhat low upper normal limits were stated no doubt producing high frequency of elevated levels in carcinoma patients and also in patients with benign diseases and in healthy subjects. Thus, the lack of true cancer specificity is seen äs the main drawback of the known tumour marker substances.
To date, more rational studies have been undertaken to evaluate the role of tumour markers. Extensive clinical investigations have revealed that the value of tumour markers does not necessarily lie in their use for cancer screening and for early diagnosis (82, 83, 84 ); a considerable amount of pertinent data indicate that tumour markers help in prognosis and in monitoring cancer treatment äs an adjunctive tool for the clinical and physical examination (85, 86, 87) .
Urinary neopterin seems to be a sensitive marker compared with the best established biochemical markers, such äs polyamines for haematologic (96) and carcinoembryonic antigen for gynaecologic tumours (97) . Such a comparison would require measurement of all three markers concurrently in a study of the same patients. At present, only results of different authors are available. The problems inherent when comparing such results are the clinical examination and the considerable difference of the upper normal limits used. This variab ility in the upper normal limits seems to limit the usefulness of the CEA assay äs a tumour marker at the present time. For the reasons stated, the occurrence of elevated levels of the three markers shown in table 6 has to be interpreted with caution.
However, in table 6 there is some evidence that the sensitivity of the urinary neopterin assay is at least comparable with that of polyamine sampling for haematologic neoplasias. The polyamines äs tumour associated markers require determination of three components (putrescine, spermidine and spetminer). Therefore we believe that the neopterin technique is superior tp the polyamines method with respect to rapidity arid applicability to routine analysis. Apart fröm this methodic aspect, the biological mechanism involved in the excretioii of neopterin differs distinctly frpm that of polyamines. No statistically significant difference of neopterin levels between treated and untreäted patients was observed (49) . In contrast, a correlatiori between increase of spermine arid spermidihe with cell death due to treatment has been reported (98).
In table 6, the neopterin assay is compared to the CEA assay äs the best biochemical marker for carcinomas of the female genital träct at the present time. tt has to be npted that the neopterin estimation i § not inferior with respect to sensitivity. Most diagnostic difficulties of carcinomas in the female genital tract are encöuntered in carcinoma of the qvary. In contrast to the CEA resülts the incidence of neopterin elevations was found to be particülarly high for this type of carcinoma. Therefore, the determination of urinary neopterin levels in additiöri to the X-ray and clinical fmdings would be öf benifit for the clinician in the manägement öf ovarian cancer. At present, pfospective studies on the clinical applications of neopterin levels have -still not been performed. We emphasize that neopterin elevations associated with tumours were first described in 1979 (43) Since the neopterin assay is still at an early stage of development its biological role remains open. Results presented in table 4 and S indicate that high mean urinary neopterin levels and a high incidence of elevations occur particularly in undifferentiated neoplasias. The lowest occurrence of elevated levels obtained in patients with carcinoma of the cervix appears to reflect a poor clinical correlation of urinary neopterin levels in well differentiated solid tumours of epithelial origin. Current experiments with mixed lymphocyte cultures (unpublished) explain that the neopterin excretion is associated with activation of T-lymphocytes. As already supposed (76) elevated neopterin levels seem to represent end products of a host response -the cell mediated immunity -against the tumour. This hypothesis is consistent with the high neopterin levels observed in patients with viral infection (43) which activates T-lymphocytes.
Conclusions
HPLC on reversed phase enables the determination of urinary pteridines with satisfactory sensitivity, accuracy and practicability, äs is necessary for tumour markers in routine clinical laboratory use.
In this survey, an association was indicated between enhanced or dedifferentiated proliferation and release of pteridines into cell culture media or urine. Further, high pteridine Contents in rapidly growing tissues were demonstrated. There are several reports that have confirmed raised ' neopterin levels in patients with malignancies in advanced disease of various types. For the clinical Utility of the neopterin assay it is advantageous that neopterin levels above the upper normal limit rarely occur in healthy adults or in patients with benign diseases and occur only in a low percentage of patients with neoplasias in remission.
The urinary neopterin assay has been tested in detail for two homogeneous groups of malignancies, namely haematological and gynaecological neoplasias. Correlations to clinical staging, to well established clinical features and laboratory data have been shown. Furthermore, it appears that the neopterin determination aids the monitoring of therapy in cancer patients.
The frequency of urinary neopterin elevations was compared with literature data of polyamines äs markers for haematologic, and of CEA äs marker for gynaecologic neoplasias. The'urinary neopterin assay is at least comparable to these assays.
In summary, the results of the urinary neopterin measurement are encouraging. Further exploration of the clinical application should be pursued particülarly in poorly differentiated neoplasias of non epithelial origin.
